Intellia Therapeutics NTLA-2001 for ATTR Granted Orphan Drug Designation by the EC
Intellia Therapeutics (NTLA) announced that the European Commission (EC) has granted its product NTLA-2001 orphan drug designation.
The investigational product is being developed as a treatment for transthyretin amyloidosis (ATTR), a rare condition that can impact a number of organs and tissues within the . . .